EU: Benefits of J&J vaccine outweigh risks despite possible link to rare clotting condition

The European Medicines Agency (EMA) on Tuesday said that the overall benefit-risk for Johnson & Johnson’s COVID-19 vaccine “remains positive” despite six reports of extremely rare but severe clotting issues in the U.S.

In addition, the EMA — the top medical regulatory body of the European Union — recommended adding a warning label to the vaccines packaging that lists “very rare cases of unusual blood clots with low blood platelets” as a side effect of the vaccine.

The FDA and the CDC recommended a pause in the use of the Johnson & Johnson vaccine last week after a sixth person suffered the rare clotting disorder. About 7 million people in the U.S. safely received a dose of the vaccine before the pause.

Over the weekend, President Joe Biden’s top medical adviser, Dr. Anthony Fauci, said he expects the Johnson & Johnson pause to be lifted later this week.

This story is breaking and will be updated.

.Page-below > .RichTextModule {display:none;} .Page-below .Link {font-size: 12px; padding: 5px 10px;border: 1px solid #005687;border-radius: 4px;font-family: “proxima-nova”, sans-serif; }